Chronic Hepatitis C Virus Infection

JAMA

Volumn 289, Issue 18, 2003, Pages 2413-2417

  Flamm, Steven L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; HEPATITIS C ANTIGEN; PARACETAMOL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ALOPECIA; ANOREXIA; AUTOIMMUNE DISEASE; BODY WEIGHT DISORDER; CHILL; CHRONIC HEPATITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; COUGHING; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE TRANSMISSION; DYSPNEA; ECZEMA; ENZYME IMMUNOASSAY; FATIGUE; FEVER; HEADACHE; HEART FAILURE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INJECTION SITE; INSOMNIA; IRRITABILITY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MENTAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SLEEP DISORDER; TERATOGENICITY; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT CONTRAINDICATION; VIROLOGY; VIRUS INFECTION; WEIGHT REDUCTION; DRUG CONTRAINDICATION; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; PATHOPHYSIOLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS; RIBAVIRIN; VIRAL LOAD;

EID: 0037979127     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.18.2413     Document Type: Review

References (34)

1. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and geno-types. Semin Liver Dis. 1995;15:41-63.
2. Major M, Feinstone SM. The molecular biology of hepatitis C. Hepatology. 1997;25:1527-1538.
3. Alter MJ, Kniszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1998 through 1994. N Engl J Med 1999;341:556-562.
4. Williams I, Epidemiology of hepatitis C in the United States. Am J Med. 1999;107:2S-9S.
5. Flamm SL, Parker RA, Chopra S. Risk factors associated with chronic hepatitis C virus infection: limited frequency of an unidentifiable source of transmission. Am J Gastroenterol. 1998;93:597-600.
6. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998;47:1-33.
7. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology. 2002;36:S99-S105.
8. Feldman JG, Minkoff H, Landesman S, Dehovitz J. Heterosexual transmission of hepatitis C, hepatitis B, and HIV-1 in a sample of inner city women. Sex Transm Dis. 2000;27:338-342.
9. Osmond DH, Padian NS, Sheppard HW, et al. Risk factors for hepatitis C virus seropositivity in heterosexual couples. JAMA. 1993;269:361-365.
10. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore: an analysis of 309 sex partnerships. J Infect Dis. 1995;171:768-775.
11. Osmond DH, Charlebois E, Sheppard HW, et al. Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men. J Infect Dis. 1993;167:66-71.
12. Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology. 2001;34:223-229.
13. Colin C, Lanoir D, Touzet S, et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat. 2001;8:87-95.
14. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17-35.
15. HoofnagleJH. Hepatitis C: clinical spectrum of disease. Hepatology. 1997;26(suppl 1):15S-20S.
16. Freeman AJ, Dore GJ, Low MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34:809-816.
17. Tong MJ, El-Farra NS, Reijes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-1466.
18. Ostapowicz G, Watson KG, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus. Hepatology. 1998;27:1730-1735.
19. Hourigan LF, MacDonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1215-1219.
20. McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol. 1995;90:1250-1257.
21. Zeuzem S, Franka A, Lee JH, et al. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests and histology. Hepatology. 1996;24:1003-1009.
22. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997;25:754-758.
23. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21-S29.
24. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358-958-965.
25. Fried MW, Shiffman ML, Reddy RK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
26. McHutchison JG, Davis GL, Esteban-Mur R, et al. Durability of sustained virologic response in patients with chronic C after treatment with interferon α-2b alone or in combination with ribavirin [abstract]. Hepatology. 2001;34:244A.
27. Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40kD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind multicentre study examining effect of duration of treatment and RBV dose. J Hepatol. 2002;36(suppl 1):3.
28. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology. 2002;36:S145-S151.
29. Fried MW, Shiffman ML, Reddy RK, et al. Peg interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
30. Wasserman R, Brau N, Hassanein T, et al. Once weekly epoetin-alfa increases hemoglobin and decreases RBV discontinuation among HCV patients who develop anemia on RBV/INF therapy [abstract]. Hepatology. 2000;32:368A.
31. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-1069.
32. Flamm SL, Eshelman A, Lyons M, et al. Improved medication adherence with cognitive behavioral therapy in patients receiving pegylated interferon alfa 2b (1.5 mcg/kg week) + ribavirin (800-1400 mg day): results of a prospective, randomized, controlled, multi-center trial [abstract]. Hepatology. 2002;36;311A.
33. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology. 2002;36:S3-S20.
34. McHutchison JG, Patel K. Future therapy of hepatitis C. Hepatology, 2002;36:S245-S252.